Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 100,000 shares of the business's stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $10.65, for a total transaction of $1,065,000.00. Following the transaction, the chief operating officer now owns 896,869 shares of the company's stock, valued at approximately $9,551,654.85. This represents a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Eric Venker also recently made the following trade(s):
- On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The stock was sold at an average price of $10.42, for a total transaction of $2,271,987.22.
- On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.28, for a total transaction of $1,128,000.00.
- On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total value of $2,050,704.16.
- On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The shares were sold at an average price of $11.82, for a total value of $2,090,958.00.
- On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.49, for a total transaction of $1,149,000.00.
Roivant Sciences Trading Up 3.5 %
Shares of ROIV traded up $0.36 during trading hours on Friday, reaching $10.74. The stock had a trading volume of 5,955,106 shares, compared to its average volume of 4,288,553. The firm has a 50-day simple moving average of $11.10 and a 200 day simple moving average of $11.58. Roivant Sciences Ltd. has a 12 month low of $9.76 and a 12 month high of $13.06. The company has a market capitalization of $7.66 billion, a price-to-earnings ratio of -71.60 and a beta of 1.25.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, equities analysts forecast that Roivant Sciences Ltd. will post -0.92 EPS for the current year.
Wall Street Analyst Weigh In
Several research firms have issued reports on ROIV. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a report on Thursday, January 30th. HC Wainwright reissued a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Tuesday, February 11th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Roivant Sciences currently has a consensus rating of "Buy" and an average target price of $18.08.
Check Out Our Latest Analysis on ROIV
Institutional Trading of Roivant Sciences
Institutional investors and hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. grew its holdings in Roivant Sciences by 478.6% during the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after buying an additional 1,948 shares in the last quarter. Gladius Capital Management LP purchased a new position in shares of Roivant Sciences in the 3rd quarter worth approximately $35,000. US Bancorp DE grew its holdings in shares of Roivant Sciences by 146.5% in the third quarter. US Bancorp DE now owns 3,278 shares of the company's stock valued at $38,000 after acquiring an additional 1,948 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in shares of Roivant Sciences during the fourth quarter valued at approximately $39,000. Finally, GAMMA Investing LLC lifted its holdings in Roivant Sciences by 57.0% during the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after acquiring an additional 1,288 shares during the period. 64.76% of the stock is owned by hedge funds and other institutional investors.
About Roivant Sciences
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
See Also
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
